Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2020

01-12-2020 | Glioma | Primary research

Long noncoding RNA DANCR knockdown inhibits proliferation, migration and invasion of glioma by regulating miR-135a-5p/BMI1

Authors: Lei Feng, Tao Lin, Haijiang Che, Xiaoming Wang

Published in: Cancer Cell International | Issue 1/2020

Login to get access

Abstract

Background

Glioma is the most common and aggressive primary brain tumor with high mortality rate around the world. LncRNAs have been identified to play key roles in tumorigenesis in various cancers, including glioma. However, the precise mechanism of DANCR in progression of glioma remains poorly defined.

Methods

The expression levels of DANCR, miR-135a-5p and BMI1 were measured by qRT-PCR in glioma tissues and cells. Cell proliferation, migration and invasion were detected by CCK-8 assay and transwell assay, respectively. The possible binding sites of miR-135a-5p and DANCR or BMI1 were predicted by online software and verified using luciferase report assay and RNA immunoprecipitation (RIP) assay. Western blot analysis was carried out to detect the protein of BMI1 expression. A xenograft tumor model was established to investigate the functions of DANCR in glioma progression in vivo.

Results

DANCR was upregulated and miR-135a-5p was downregulated in glioma tissues and cells. Knockdown of DANCR inhibited cell proliferation, migration and invasion in glioma cells. In addition, miR-135a-5p was a direct target of DANCR, and its elevated expression could reverse miR-135a-5p inhibition-mediated progression of glioma. Moreover, miR-135a-5p could specially bind to BMI1, and the expression of BMI1 was obviously elevated in glioma tissues and cells. Furthermore, DANCR acted as a ceRNA to regulate BMI1 expression and BMI1-mediated effects on progression of glioma by sponging miR-135a-5p. Besides, inhibition of DANCR limited tumor growth by regulating miR-135a-5p and BMI1 expression in vivo.

Conclusion

DANCR knockdown inhibited cell proliferation, migration and invasion in glioma cells through regulating miR-135a-5p/BMI1 axis, providing viable therapeutic avenues for treatment of glioma.
Appendix
Available only for authorised users
Literature
1.
Michael J, Stephen Y, Louis DN. Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers. Lancet Neurol. 2010;9(7):717–26.CrossRef
2.
Hadjipanayis CG, Meir EGV. Tumor initiating cells in malignant gliomas: biology and implications for therapy. J Mol Med. 2009;87(4):363.CrossRef
3.
Benjamin P, David S. Advances in the genetics of glioblastoma: are we reaching critical mass? Nature Rev Neurol. 2009;5(8):419–26.CrossRef
4.
Wilusz JE, Hongjae S, Spector DL. Long noncoding RNAs: functional surprises from the RNA world. Genes Dev. 2009;23(13):1494–504.CrossRef
5.
Sun Y, Wang Z, Zhou D. Long non-coding RNAs as potential biomarkers and therapeutic targets for gliomas. Med Hypotheses. 2013;81(2):319–21.CrossRef
6.
Wang Y, Wang Y, Li J, Zhang Y, Yin H, Han B. CRNDE, a long-noncoding RNA, promotes glioma cell growth and invasion through mTOR signaling. Cancer Lett. 2015;367(2):122–8.CrossRef
7.
Wang A, Meng M, Zhao X, Kong L. Long non-coding RNA ENST00462717 suppresses the proliferation, survival, and migration by inhibiting MDM2/MAPK pathway in glioma. Biochem Biophys Res Commun. 2017;485(2):513–21.CrossRef
8.
Jia J, Li F, Tang XS, Xu S, Gao Y, Shi Q, Guo W, Wang X, He D, Guo P. Long noncoding RNA DANCR promotes invasion of prostate cancer through epigenetically silencing expression of TIMP2/3. Oncotarget. 2016;7(25):37868–81.CrossRef
9.
Imram I, Ziaulhaq M, Calani L, Mazzeo T, Pellegrini N. Over-expression of lncRNA DANCR is associated with advanced tumor progression and poor prognosis in patients with colorectal cancer. Int J Clin Exp Pathol. 2015;8(9):11480.
10.
Mao Z, Li H, Du B, Cui K, Xing Y, Zhao X, Zai S. LncRNA DANCR promotes migration and invasion through suppression of lncRNA-LET in gastric cancer cells. Biosci Rep. 2017;37(6):BSR20171070.CrossRef
11.
Li J, Zhou L. Overexpression of lncRNA DANCR positively affects progression of glioma via activating Wnt/β-catenin signaling. Biomed Pharmacother. 2018;102:602–7.CrossRef
12.
Li F, Li Q, Wu X. Construction and analysis for differentially expressed long non-coding RNAs and microRNAs mediated competing endogenous RNA network in colon cancer. PLoS ONE. 2018;13(2):e0192494.CrossRef
13.
Ga C, Cm C. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6(11):857–66.CrossRef
14.
Hermansen SK. MicroRNA biomarkers in glioblastoma. J Neurooncol. 2013;114(1):13–23.CrossRef
15.
Luo W, Sun C, Zhou J, Wang Q, Yu L, Bian XW, Zhou X, Hua D, Wang R, Rao C. miR-135a-5p functions as a glioma proliferation suppressor by targeting TRAF5 and predicts patients’ prognosis. Am J Pathol. 2019;189(1):162–76.CrossRef
16.
Zhang F, Sui L, Xin T. Correlations of BMI-1 expression and telomerase activity in ovarian cancer tissues. Exp Oncol. 2008;30(1):70–4.PubMed
17.
Kim JH, Yoon SY, Kim CN, Joo JH, Moon SK, Choe IS, Choe YK, Kim JW. The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteins. Cancer Lett. 2004;203(2):224.
18.
Vonlanthen S, Heighway J, Altermatt HJ, Gugger M, Kappeler A, Borner MM, Van LM, Betticher DC. The Bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A–ARF locus expression. Br J Cancer. 2001;84(10):1372–6.CrossRef
19.
Kim JH, Yoon SY, Jeong SH, Kim SY, Moon SK, Joo JH, Lee Y, Choe IS, Kim JW. Overexpression of Bmi-1 oncoprotein correlates with axillary lymph node metastases in invasive ductal breast cancer. Breast. 2004;13(5):383–8.CrossRef
20.
Jakub G, Nowicki MO, Agnieszka B, Shanté W, Akihiro O, Gerard N, Abhik R, Newton HB, Antonio EC, Sean L. Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self renewal. Cancer Res. 2008;68(22):9125.CrossRef
21.
Jana N, Ondrej S, Rostislav V, Jaroslav M. MicroRNA involvement in glioblastoma pathogenesis. Biochem Biophys Res Commun. 2009;386(1):1–5.CrossRef
22.
Lefranc F, Rynkowski M, Dewitte O, Kiss R. Present and potential future adjuvant issues in high-grade astrocytic glioma treatment. Adv Tech Stand Neurosurg. 2009;34:3–35.CrossRef
23.
Yan Y, Xu Z, Li Z, Sun L, Gong Z. An Insight into the Increasing Role of LncRNAs in the pathogenesis of gliomas. Front Mol Neurosci. 2017;10(24516):53.PubMedPubMedCentral
24.
Ma X, Wang X, Yang C, Wang Z, Han B, Wu L, Zhuang L. DANCR acts as a diagnostic biomarker and promotes tumor growth and metastasis in hepatocellular carcinoma. Anticancer Res. 2016;36(12):6389–98.CrossRef
25.
Thin KZ, Liu X, Feng X, Raveendran S, Tu JC. LncRNA-DANCR: a valuable cancer related long non-coding RNA for human cancers. Pathol Res Pract. 2018;214(6):801.CrossRef
26.
Yvonne T, John R, Pier Paolo P. The multilayered complexity of ceRNA crosstalk and competition. Nature. 2014;505(7483):344–52.CrossRef
27.
Xu D, Yu J, Gao G, Lu G, Zhang Y, Ma P. LncRNA DANCR functions as a competing endogenous RNA to regulate RAB1A expression by sponging miR-634 in glioma. Biosci Rep. 2018;38(1):BSR20171664.CrossRef
28.
Yang JX, Sun Y, Gao L, Meng Q, Yang BY. Long non-coding RNA DANCR facilitates glioma malignancy by sponging miR-33a-5p. Neoplasma. 2018;65(5):790–8.CrossRef
29.
Guo LM, Ding GF, Xu W, Ge H, Jiang Y, Chen XJ, Lu Y. MiR-135a-5p represses proliferation of HNSCC by targeting HOXA10. Cancer Biol Ther. 2018;7:1–28.
30.
Zhao X, Sun Z, Li H, Jiang F, Zhou J, Zhang L. MiR-135a-5p modulates biological functions of thyroid carcinoma cells via targeting VCAN 3′-UTR. Cancer Biomarkers. 2017;20(2):207–16.CrossRef
31.
Bao-Hong G, Yan F, Rong Z, Li-Hua X, Man-Zhi L, Hsiang-Fu K, Li-Bing S, Mu-Sheng Z. Bmi-1 promotes invasion and metastasis, and its elevated expression is correlated with an advanced stage of breast cancer. Mol Cancer. 2011;10(1):10.CrossRef
32.
Kim JH, Yoon SY, Kim CN, Joo JH, Moon SK, Choe IS, Choe YK, Kim JW. The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteins. Cancer Lett. 2004;203(2):217–24.CrossRef
33.
Jun L, Li-Yun G, Li-Bing S, Li-Li J, Li-Ping L, Jueheng W, Jie Y, Jun-Chao C, Mian H, Lan W. Oncoprotein Bmi-1 renders apoptotic resistance to glioma cells through activation of the IKK-nuclear factor-kappaB Pathway. Am J Pathol. 2010;176(2):699–709.CrossRef
Metadata
Title
Long noncoding RNA DANCR knockdown inhibits proliferation, migration and invasion of glioma by regulating miR-135a-5p/BMI1
Authors
Lei Feng
Tao Lin
Haijiang Che
Xiaoming Wang
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2020
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-020-1123-4

Other articles of this Issue 1/2020

Cancer Cell International 1/2020 Go to the issue

Review

LncRNA & Wnt signaling in colorectal cancer

Correction

Correction to: Virotheranostics, a double-barreled viral gun pointed toward cancer; ready to shoot?

Primary research

ZBTB7A, a potential biomarker for prognosis and immune infiltrates, inhibits progression of endometrial cancer based on bioinformatics analysis and experiments

Primary research

A novel risk score system of immune genes associated with prognosis in endometrial cancer

Primary research

High-throughput sequencing identification of differentially expressed microRNAs in metastatic ovarian cancer with experimental validations

Primary research

Long non-coding RNA LINC01419 mediates miR-519a-3p/PDRG1 axis to promote cell progression in osteosarcoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits